STRO Stock Forecast & Price Target

Sutro Biopharma is viewed favorably because its lead asset STRO-004 is showing early multi-histology activity in a heavily pretreated, TF-unselected population, with confirmed and unconfirmed partial responses in PDAC, HNSCC, and NSCLC, while preserving a differentiated safety profile marked by a 6% discontinuation rate and limited high-grade ocular or neuropathic toxicity. The platform thesis is strengthened by encouraging pharmacokinetics, including dose-proportional exposure, a nearly seven-day half-life, and 98% preservation of the DAR8 configuration, alongside expanding preclinical evidence such as a 62% ORR in 97 PDX models and supportive combination data with talazoparib. With STRO-006 and STRO-227 advancing toward clinic entry or IND filing, and $164.3MM in cash expected to fund operations into at least 2Q28, the company has multiple near-term catalysts and sufficient balance sheet support to develop a broader ADC pipeline.

Sutro Biopharma is exposed to substantial fundamental downside because its valuation depends heavily on lead ADC candidates that could deliver poorer-than-expected clinical results, forcing lower market penetration assumptions, higher discount rates, and delayed or nonexistent approvals. Its broader pipeline, including partnered and wholly-owned discovery and preclinical assets, faces the same clinical, regulatory, and commercialization uncertainty, while intense competition from larger biotech and pharmaceutical rivals raises the odds of weaker differentiation and reimbursement pressure. Although it is currently well-funded with cash, cash equivalents, and short-term investments, the company may still need additional equity financing to complete development, which could dilute shareholders if progress stalls.